IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass

Journal of Immunology

Volumn 187, Issue 2, 2011, Pages 951-959

  Adamopoulos, Iannis E ^a,b   Tessmer, Marlowe ^a   Chao, Cheng Chi ^a   Adda, Sarvesh ^a   Gorman, Dan ^a   Petro, Mary ^a   Chou, Chuan Chu ^a   Pierce, Robert H ^a   Yao, Wei ^b   Lane, Nancy E ^b   Laface, Drake ^a   Bowman, Edward P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MASS; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; MYELOPOIESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN; TRABECULAR BONE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CELL DIFFERENTIATION; CHO CELLS; CHRONIC DISEASE; CRICETINAE; CRICETULUS; DNA, KINETOPLAST; HEK293 CELLS; HUMANS; INTERLEUKIN-23 SUBUNIT P19; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOCLASTS; SEVERITY OF ILLNESS INDEX; SPLEEN;

EID: 79960492398     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003986     Document Type: Article

References (34)

1. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
2. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176. (Pubitemid 28180851)
3. Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Lüthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. (Pubitemid 27199902)
4. Li, J., I. Sarosi, X.-Q. Yan, S. Morony, C. Capparelli, H.-L. Tan, S. McCabe, R. Elliott, S. Scully, G. Van, et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571.
5. Kong, Y. Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309. (Pubitemid 129516268)
6. Kobayashi, K., N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191: 275-286.
7. Azuma, Y., K. Kaji, R. Katogi, S. Takeshita, and A. Kudo. 2000. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275: 4858-4864.
8. Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M. T. Gillespie, et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103: 1345-1352.
9. Adamopoulos, I. E., and E. P. Bowman. 2008. Immune regulation of bone loss by Th17 cells. Arthritis Res. Ther. 10: 225.
10. Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673-2682.
11. Adamopoulos, I. E., C. C. Chao, R. Geissler, D. Laface, W. Blumenschein, Y. Iwakura, T. McClanahan, and E. P. Bowman. 2010. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res. Ther. 12: R29.
12. Yu, J. J., M. J. Ruddy, G. C. Wong, C. Sfintescu, P. J. Baker, J. B. Smith, R. T. Evans, and S. L. Gaffen. 2007. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 109: 3794-3802.
13. Yu, J. J., M. J. Ruddy, H. R. Conti, K. Boonanantanasarn, and S. L. Gaffen. 2008. The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect. Immun. 76: 4206-4213.
14. Goswami, J., N. Hernández-Santos, L. A. Zuniga, and S. L. Gaffen. 2009. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur. J. Immunol. 39: 2831-2839.
15. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
16. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
17. Yago, T., Y. Nanke, M. Kawamoto, T. Furuya, T. Kobashigawa, N. Kamatani, and S. Kotake. 2007. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9: R96.
18. Chen, L., X. Q. Wei, B. Evans, W. Jiang, and D. Aeschlimann. 2008. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NFkappaB (RANK) expression in myeloid precursor cells. Eur. J. Immunol. 38: 2845-2854.
19. Quinn, J. M., N. A. Sims, H. Saleh, D. Mirosa, K. Thompson, S. Bouralexis, E. C. Walker, T. J. Martin, and M. T. Gillespie. 2008. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J. Immunol. 181: 5720-5729.
20. Chao, C. C., S. J. Chen, I. E. Adamopoulos, M. Judo, A. Asio, G. Ayanoglu, and E. P. Bowman. 2010. Structural, cellular, and molecular evaluation of bone erosion in experimental models of rheumatoid arthritis: assessment by mCT, histology, and serum biomarkers. Autoimmunity 43: 642-653.
21. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748. (Pubitemid 36227625)
22. Suda, T., and D. Liu. 2007. Hydrodynamic gene delivery: its principles and applications. Mol. Ther. 15: 2063-2069.
23. Chen, Z. Y., C. Y. He, and M. A. Kay. 2005. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum. Gene Ther. 16: 126-131.
24. Chao, C. C., S. J. Chen, I. E. Adamopoulos, N. Davis, K. Hong, A. Vu, S. Kwan, L. Fayadat-Dilman, A. Asio, and E. P. Bowman. 2010. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44: 243-252.
25. Lane, N. E., W. Yao, M. Balooch, R. K. Nalla, G. Balooch, S. Habelitz, J. H. Kinney, and L. F. Bonewald. 2006. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21: 466-476.
26. Wiekowski, M. T., M. W. Leach, E. W. Evans, L. Sullivan, S. C. Chen, G. Vassileva, J. F. Bazan, D. M. Gorman, R. A. Kastelein, S. Narula, and S. A. Lira. 2001. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166: 7563-7570.
27. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031. (Pubitemid 21905432)
28. Nair, R. P., K. C. Duffin, C. Helms, J. Ding, P. E. Stuart, D. Goldgar, J. E. Gudjonsson, Y. Li, T. Tejasvi, B. J. Feng, et al; Collaborative Association Study of Psoriasis. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41: 199-204.
29. Buonocore, S., P. P. Ahern, H. H. Uhlig, I. I. Ivanov, D. R. Littman, K. J. Maloy, and F. Powrie. 2010. Innate lymphoid cells drive interleukin-23- dependent innate intestinal pathology. Nature 464: 1371-1375.
30. Chen, Z. Y., C. Y. He, A. Ehrhardt, and M. A. Kay. 2003. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 8: 495-500.
31. McGeachy, M. J., K. S. Bak-Jensen, Y. Chen, C. M. Tato, W. Blumenschein, T. McClanahan, and D. J. Cua. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8: 1390-1397.
32. Rivollier, A., M. Mazzorana, J. Tebib, M. Piperno, T. Aitsiselmi, C. Rabourdin-Combe, P. Jurdic, and C. Servet-Delprat. 2004. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104: 4029-4037. (Pubitemid 39620153)
33. Arai, F., T. Miyamoto, O. Ohneda, T. Inada, T. Sudo, K. Brasel, T. Miyata, D. M. Anderson, and T. Suda. 1999. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190: 1741-1754.
34. Jacquin, C., D. E. Gran, S. K. Lee, J. A. Lorenzo, and H. L. Aguila. 2006. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Miner. Res. 21: 67-77.